Neurovalens successfully secured 510(k) clearance from the FDA on October 27, 2023 for its Modius Sleep device with relation to treatment of insomnia and/or anxiety. The clearance was supported by ...
MedPage Today on MSN
FDA approves neuromodulation device to treat PTSD symptoms
Military veterans will have first access to Modius Spero vestibular stimulation ...
95 percent of clinical trial participants reported better sleep in four weeks BELFAST, Northern Ireland, Oct. 28, 2024 /PRNewswire/ -- Neurovalens, a global health-tech leader in neurotechnology, has ...
The Food and Drug Administration granted de novo approval to Modius Spero, marking it the world’s first neuromodulation device authorized to ...
Neurovalens continues to run clinical trials on effectiveness of other drug-free non-invasive technology ...
BELFAST, Northern Ireland, Feb. 24, 2025 /PRNewswire/ -- Neurovalens, a global leader in noninvasive neurostimulation technology, is making significant strides in addressing chronic insomnia among U.S ...
Being granted medical device regulatory approval for Modius Spero from the FDA validates it as a treatment for patients who ...
A neurotech firm in Northern Ireland has been given the US green light for its headset to be used for treating post-traumatic stress disorder (PTSD). As a result, Neurovalens’ Modius Spero will be ...
Neurovalens Ltd raised £6 million (US$8 million) in an investment round for its non-invasive neurostimulation devices, which treat insomnia and manage anxiety. The company will use the funds to expand ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results